Evolent Health (EVH) Tops Q3 EPS by 23c; Offers FY23 Revenue Guidance
Evolent Health (NYSE: EVH) reported Q3 EPS of $0.30, $0.23 better than the analyst estimate of $0.07. Revenue for the quarter came in at $511 million versus the consensus estimate of $509.21 million.
GUIDANCE:
Evolent Health sees FY2023 revenue of $1.95-1.97 billion, versus the consensus of $1.95 billion.
For earnings history and earnings-related data on Evolent Health (EVH) click here.
